LBL-051
Severe Autoimmune Diseases
Pre-clinicalActive
Key Facts
About Oblenio Bio
Oblenio Bio is a private, pre-clinical stage biotech focused on developing a first-in-class, tri-specific T-cell engager antibody, LBL-051, which dually targets CD19 and BCMA for the treatment of autoimmune diseases. Formed as an Aditum Bio company in November 2024 following an exclusive option to license LBL-051 from Leads Biolabs, the company aims to deplete pathological B-cell lineages to achieve a robust and durable immune reset. Oblenio Bio is positioned to tackle difficult treatment challenges across a broad spectrum of autoimmune conditions with this potentially paradigm-shifting therapeutic approach.
View full company profile